研究单位：[1]The George Institute[2]Concord Repatriation and General Hospital Concord, New South Wales, Australia, 2139[3]Nepean Hospital Kingswood, New South Wales, Australia, 2747[4]ongji Hospital, Tongji Medical College, Huazhong University of Science & Technology Wuhan, Hubei, China, 430022[5]Peking University
This study will evaluate the long-term efficacy and safety of low dose oral methylprednisolone compared to matching placebo, on a background of routine RAS inhibitor therapy, in preventing kidney events in patients with IgA nephropathy and features suggesting a high risk of progression.
